Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.4 USD | +1.84% | -2.78% | +1.59% |
Financials (USD)
Sales 2024 * | 601M | Sales 2025 * | 615M | Capitalization | 1.61B |
---|---|---|---|---|---|
Net income 2024 * | 7M | Net income 2025 * | -24M | EV / Sales 2024 * | 2.68 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.62 x |
P/E ratio 2024 * |
-2,940
x | P/E ratio 2025 * |
-68.4
x | Employees | 652 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.88% |
Latest transcript on Supernus Pharmaceuticals, Inc.
1 day | +1.84% | ||
1 week | -2.78% | ||
Current month | -13.81% | ||
1 month | -16.36% | ||
3 months | +6.25% | ||
6 months | +23.63% | ||
Current year | +1.59% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 15-03-22 |
Charles Newhall
CHM | Chairman | 79 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.94% | 29 M€ | -5.60% | ||
0.94% | 16 M€ | -9.75% | ||
0.38% | 27 M€ | -5.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 29.4 | +1.84% | 361,633 |
24-04-18 | 28.87 | -0.45% | 347,896 |
24-04-17 | 29 | -1.46% | 393,830 |
24-04-16 | 29.43 | -1.87% | 388,897 |
24-04-15 | 29.99 | -0.83% | 372,719 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.59% | 1.58B | |
+10.08% | 9.12B | |
-17.63% | 4.8B | |
+0.73% | 3.8B | |
+16.55% | 3.72B | |
+27.76% | 2.58B | |
-26.11% | 2.36B | |
-30.09% | 2.11B | |
+7.15% | 1.86B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock